Literature DB >> 18614776

Pulmonary hypertension, right ventricular failure, and kidney: different from left ventricular failure?

Robert W Schrier1, Shweta Bansal.   

Abstract

In this article, the pathophysiology of left ventricular failure is reviewed. By contrast, the paucity of information about pulmonary arterial hypertension and right ventricular failure is acknowledged. The potential mechanisms whereby renal sodium and water retention in right ventricular failure secondary to pulmonary arterial hypertension can occur, despite normal left ventricular function, are discussed. With right ventricular failure as the primary cause of death in patients with pulmonary hypertension, more information about the mechanisms of renal sodium and water retention in these patients is direly needed. Specifically, studies to examine the activation of the neurohumoral axis at various stages of pulmonary arterial hypertension and right ventricular failure, including inhibition of mineralocorticoid and V2 vasopressin receptors, are indicated.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18614776      PMCID: PMC4571151          DOI: 10.2215/CJN.01960408

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  46 in total

Review 1.  Renal and hormonal abnormalities in chronic obstructive pulmonary disease (COPD).

Authors:  P Palange
Journal:  Thorax       Date:  1998-11       Impact factor: 9.139

2.  Reflex changes in hindlimb and renal vascular resistance in response to distention of the isolated pulmonary arteries of the dog.

Authors:  J R Ledsome; W O Kan
Journal:  Circ Res       Date:  1977-01       Impact factor: 17.367

3.  Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry.

Authors:  Mihai Gheorghiade; William T Abraham; Nancy M Albert; Wendy Gattis Stough; Barry H Greenberg; Christopher M O'Connor; Lilin She; Clyde W Yancy; James Young; Gregg C Fonarow
Journal:  Eur Heart J       Date:  2007-02-19       Impact factor: 29.983

Review 4.  Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor?

Authors:  Robert W Schrier
Journal:  J Am Coll Cardiol       Date:  2005-12-15       Impact factor: 24.094

Review 5.  Primary pulmonary hypertension.

Authors:  S P Gaine; L J Rubin
Journal:  Lancet       Date:  1998-08-29       Impact factor: 79.321

6.  Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention.

Authors:  J Hensen; W T Abraham; J A Dürr; R W Schrier
Journal:  Am J Nephrol       Date:  1991       Impact factor: 3.754

7.  Pericardial adaptation in severe chronic pulmonary hypertension. An intraoperative transesophageal echocardiographic study.

Authors:  D G Blanchard; H C Dittrich
Journal:  Circulation       Date:  1992-04       Impact factor: 29.690

Review 8.  Decreased effective blood volume in edematous disorders: what does this mean?

Authors:  Robert W Schrier
Journal:  J Am Soc Nephrol       Date:  2007-06-13       Impact factor: 10.121

9.  Atrial natriuretic peptide concentrations and pulmonary hemodynamics in patients with pulmonary artery hypertension.

Authors:  S Adnot; P E Chabrier; P Andrivet; I Viossat; J Piquet; C Brun-Buisson; Y Gutkowska; P Braquet
Journal:  Am Rev Respir Dis       Date:  1987-10

10.  Blunted natriuresis to atrial natriuretic peptide in chronic sodium-retaining disorders.

Authors:  J P Koepke; G F DiBona
Journal:  Am J Physiol       Date:  1987-05
View more
  28 in total

Review 1.  Assessment and treatment of right ventricular failure.

Authors:  Marc A Simon
Journal:  Nat Rev Cardiol       Date:  2013-02-12       Impact factor: 32.419

Review 2.  [Arrhythmias in patients with pulmonary hypertension and chronic lung disease].

Authors:  Dirk Bandorski; Reinhard Höltgen; Ardeschir Ghofrani; Viktoria Johnson; Jörn Schmitt
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2019-08-22

3.  Pulmonary arterial hypertension treatment with carvedilol for heart failure: a randomized controlled trial.

Authors:  Samar Farha; Didem Saygin; Margaret M Park; Hoi I Cheong; Kewal Asosingh; Suzy Aa Comhair; Olivia R Stephens; Emir C Roach; Jacqueline Sharp; Kristin B Highland; Frank P DiFilippo; Donald R Neumann; W H Wilson Tang; Serpil C Erzurum
Journal:  JCI Insight       Date:  2017-08-17

Review 4.  Pressure-overload-induced right heart failure.

Authors:  S Rain; M L Handoko; A Vonk Noordegraaf; H J Bogaard; J van der Velden; F S de Man
Journal:  Pflugers Arch       Date:  2014-02-01       Impact factor: 3.657

5.  QTc prolongation is associated with impaired right ventricular function and predicts mortality in pulmonary hypertension.

Authors:  Jonathan D Rich; Thenappan Thenappan; Benjamin Freed; Amit R Patel; Ronald A Thisted; Rory Childers; Stephen L Archer
Journal:  Int J Cardiol       Date:  2012-03-27       Impact factor: 4.164

Review 6.  Novel therapeutic approaches to preserve the right ventricle.

Authors:  Samar Farha; Erika L Lundgrin; Serpil C Erzurum
Journal:  Curr Heart Fail Rep       Date:  2013-03

Review 7.  Mechanisms of the cardiorenal syndromes.

Authors:  M Khaled Shamseddin; Patrick S Parfrey
Journal:  Nat Rev Nephrol       Date:  2009-09-29       Impact factor: 28.314

Review 8.  Arrhythmias in pulmonary arterial hypertension.

Authors:  Archana Rajdev; Hasan Garan; Angelo Biviano
Journal:  Prog Cardiovasc Dis       Date:  2012 Sep-Oct       Impact factor: 8.194

Review 9.  Molecular Mechanisms of Right Ventricular Failure.

Authors:  Sushma Reddy; Daniel Bernstein
Journal:  Circulation       Date:  2015-11-03       Impact factor: 29.690

10.  Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension.

Authors:  Anderson J Ferreira; Vinayak Shenoy; Yoriko Yamazato; Srinivas Sriramula; Joseph Francis; Lihui Yuan; Ronald K Castellano; David A Ostrov; Suk Paul Oh; Michael J Katovich; Mohan K Raizada
Journal:  Am J Respir Crit Care Med       Date:  2009-02-26       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.